Magnesium ascorbate

Identification

Name
Magnesium ascorbate
Accession Number
DB14484
Description
Not Available
Type
Small Molecule
Groups
Approved, Nutraceutical
Structure
Thumb
Weight
Average: 374.537
Monoisotopic: 374.03356759
Chemical Formula
C12H14MgO12
Synonyms
  • Ascorbic acid, magnesium salt
  • L(+)-ascorbic acid magnesium salt
  • Vitamin C magnesium salt

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AmphetamineThe serum concentration of Amphetamine can be decreased when it is combined with Magnesium ascorbate.
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Magnesium ascorbate.
ChlorpropamideMagnesium ascorbate may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
DextroamphetamineThe serum concentration of Dextroamphetamine can be decreased when it is combined with Magnesium ascorbate.
DiethylpropionThe serum concentration of Diethylpropion can be decreased when it is combined with Magnesium ascorbate.
Iofetamine I-123The serum concentration of Iofetamine I-123 can be decreased when it is combined with Magnesium ascorbate.
LisdexamfetamineThe serum concentration of Lisdexamfetamine can be decreased when it is combined with Magnesium ascorbate.
MecamylamineMagnesium ascorbate may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.
MephentermineThe serum concentration of Mephentermine can be decreased when it is combined with Magnesium ascorbate.
MetamfetamineThe serum concentration of Metamfetamine can be decreased when it is combined with Magnesium ascorbate.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take with or without food. Taking magnesium supplements with food may reduce the risk of diarrhea.

Products

Active Moieties
NameKindUNIICASInChI Key
Ascorbic acidunknownPQ6CK8PD0R50-81-7CIWBSHSKHKDKBQ-JLAZNSOCSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Energy 80 Prolonged Release TabMagnesium ascorbate (410 mg) + Calcium ascorbate (130 mg) + Cyanocobalamin (100 mcg) + Folic acid (25 mcg) + Pantothenic acid (25 mg) + Pyridoxine hydrochloride (25 mg)Tablet, extended releaseOralSportscience Labs Inc.1981-12-312002-06-20Canada
PramLyteMagnesium ascorbate (24 mg/1) + 1,2-docosahexanoyl-sn-glycero-3-phosphoserine calcium (6.4 mg/1) + 1,2-icosapentoyl-sn-glycero-3-phosphoserine calcium (800 ug/1) + Citric acid monohydrate (1.83 mg/1) + Cobamamide (50 ug/1) + Cocarboxylase (25 ug/1) + Escitalopram oxalate (10 mg/1) + Ferrous cysteine glycinate (13.6 mg/1) + Flavin adenine dinucleotide (25 ug/1) + Folic acid (1 mg/1) + Glycine betaine (500 ug/1) + Leucovorin (2.5 mg/1) + Levomefolate magnesium (7 mg/1) + NADH (25 ug/1) + Phosphatidyl serine (12 mg/1) + Pyridoxal phosphate (25 ug/1) + Sodium citrate (3.67 mg/1) + Zinc ascorbate (1 mg/1)KitOralAllegis Pharmaceuticals, LLC2015-09-112016-01-04Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
EnBrace HRMagnesium ascorbate (24 mg/1) + 1,2-docosahexanoyl-sn-glycero-3-phosphoserine calcium (6.4 mg/1) + 1,2-icosapentoyl-sn-glycero-3-phosphoserine calcium (800 ug/1) + Cobamamide (50 ug/1) + Cocarboxylase (25 ug/1) + Ferrous cysteine glycinate (13.6 mg/1) + Flavin adenine dinucleotide (25 ug/1) + Folic acid (1 mg/1) + Glycine betaine (500 ug/1) + Magnesium L-threonate (1 mg/1) + Leucovorin (2.5 mg/1) + Levomefolate magnesium (5.23 mg/1) + NADH (25 ug/1) + Phosphatidyl serine (12 mg/1) + Pyridoxal phosphate (25 ug/1) + Zinc ascorbate (1 mg/1)Capsule, delayed release pelletsOralJaymac Pharmaceuticals, Llc2011-08-12Not applicableUs
EnLyteMagnesium ascorbate (24 mg/1) + 1,2-docosahexanoyl-sn-glycero-3-phosphoserine calcium (6.4 mg/1) + 1,2-icosapentoyl-sn-glycero-3-phosphoserine calcium (800 ug/1) + Citric acid monohydrate (1.83 mg/1) + Cobamamide (50 ug/1) + Cocarboxylase (25 ug/1) + Ferrous cysteine glycinate (13.6 mg/1) + Flavin adenine dinucleotide (25 ug/1) + Folic acid (1 mg/1) + Glycine betaine (500 ug/1) + Magnesium L-threonate (1 mg/1) + Leucovorin (2.5 mg/1) + Levomefolate magnesium (7 mg/1) + NADH (25 ug/1) + Phosphatidyl serine (12 mg/1) + Pyridoxal phosphate (25 ug/1) + Sodium citrate (3.67 mg/1) + Zinc ascorbate (1 mg/1)Capsule, delayed release pelletsOralJaymac Pharmaceuticals Llc2011-08-12Not applicableUs

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
0N1G678593
CAS number
15431-40-0
InChI Key
AIOKQVJVNPDJKA-ZZMNMWMASA-L
InChI
InChI=1S/2C6H8O6.Mg/c2*7-1-2(8)5-3(9)4(10)6(11)12-5;/h2*2,5,7-10H,1H2;/q;;+2/p-2/t2*2-,5+;/m00./s1
IUPAC Name
magnesium(2+) bis((2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate)
SMILES
[Mg++].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO.[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO

References

General References
Not Available
ChemSpider
17339241
Wikipedia
Mineral_ascorbates

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4WithdrawnTreatmentMenstrual Related Mood Disorder / Premenstrual Dysphoric Disorder / Premenstrual Syndrome / Premenstrual tension with edema1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, extended releaseOral
Capsule, delayed release pelletsOral
CapsuleOral
KitOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility9.07 mg/mLALOGPS
logP-1.7ALOGPS
logP-1.9ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)4.36ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area110.05 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity47.58 m3·mol-1ChemAxon
Polarizability14.53 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on July 06, 2018 16:23 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates